Shares of Everest Medicines Limited (HKG:1952) soared 7.62% on October 25th, capping a remarkable 41% gain over the past week. This surge benefited the company's largest shareholder group - retail investors who collectively own 46% of the outstanding shares.
The stock's rally allowed retail investors to reap substantial gains on their investments. With such a significant ownership stake, their trading activity likely fueled the upward momentum as they capitalized on positive sentiment surrounding the biopharmaceutical company.
Beyond retail investors, Everest Medicines has a diverse ownership base. Institutional investors hold a 12% stake, while insiders own less than 1% of shares. Private equity firms also maintain a considerable 41% ownership position, giving them influence over corporate strategy. This varied investor mix contributed to the stock's impressive performance amid heightened demand.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。